Table 5.6a
Immunosuppression Use for Induction, 1996 to 2005
Recipients with Kidney Transplants

	Year of Transplant									
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005
Transplants	11,397	11,701	12,451	12,758	13,611	14,265	14,778	15,136	16,004	16,477
With Immunosuppression Info	11,158	11,608	12,335	12,486	13,252	14,120	14,600	14,934	15,731	15,820
Induction Drugs										
ALG	2.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	15.3%	17.3%	12.2%	6.6%	3.2%	2.5%	1.9%	1.1%	1.8%	1.6%
OKT3	21.4%	17.7%	10.0%	3.9%	1.8%	0.8%	0.9%	0.4%	0.3%	0.4%
Thymoglobulin	0.0%	0.0%	0.2%	4.9%	10.1%	17.1%	25.8%	33.6%	36.6%	38.6%
Zenapax	0.2%	0.2%	13.0%	16.5%	13.1%	14.4%	12.9%	12.5%	11.3%	11.5%
Simulect	0.6%	0.1%	5.0%	17.2%	26.6%	25.3%	26.4%	21.6%	19.0%	16.4%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3.6%	6.8%	8.8%
No Induction Drugs Recorded	61.5%	65.7%	61.1%	53.0%	47.7%	42.5%	35.2%	30.2%	28.0%	26.4%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.